Oral Semaglutide Reduces HbA(1c) and Body Weight in Patients with Type 2 Diabetes Regardless of Background Glucose-Lowering Medication: PIONEER Subgroup Analyses

INTRODUCTION: The efficacy and safety of oral semaglutide, the first oral glucagon-like peptide-1 receptor agonist, were investigated in patients with type 2 diabetes (T2D) in the Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) programme. The current post-hoc exploratory subgroup analyses...

詳細記述

保存先:
書誌詳細
出版年:Diabetes Ther
主要な著者: Pratley, Richard E., Crowley, Matthew J., Gislum, Mette, Hertz, Christin L., Jensen, Thomas B., Khunti, Kamlesh, Mosenzon, Ofri, Buse, John B.
フォーマット: Artigo
言語:Inglês
出版事項: Springer Healthcare 2021
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7994454/
https://ncbi.nlm.nih.gov/pubmed/33660198
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13300-020-00994-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料